Akoya Biosciences (AKYA) Expected to Announce Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $20.19 million for the quarter.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $21.34 million during the quarter, compared to the consensus estimate of $21.34 million. Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. On average, analysts expect Akoya Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Akoya Biosciences Stock Performance

Akoya Biosciences stock traded down $0.01 during mid-day trading on Wednesday, reaching $1.12. The company had a trading volume of 124,884 shares, compared to its average volume of 351,587. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The company has a 50 day moving average of $1.35 and a 200-day moving average of $2.13. Akoya Biosciences has a 52 week low of $1.01 and a 52 week high of $4.65. The firm has a market cap of $55.86 million, a price-to-earnings ratio of -0.95 and a beta of 1.34.

Institutional Trading of Akoya Biosciences

An institutional investor recently raised its position in Akoya Biosciences stock. Bank of America Corp DE increased its holdings in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Free Report) by 39.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,092 shares of the company's stock after acquiring an additional 8,258 shares during the period. Bank of America Corp DE owned about 0.06% of Akoya Biosciences worth $67,000 at the end of the most recent quarter. Institutional investors and hedge funds own 79.42% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. Canaccord Genuity Group reduced their target price on Akoya Biosciences from $3.50 to $1.80 and set a "hold" rating for the company in a research report on Tuesday, April 29th. Piper Sandler lowered their target price on shares of Akoya Biosciences from $2.40 to $1.65 and set a "neutral" rating on the stock in a research note on Monday, April 14th. Finally, Stephens restated an "equal weight" rating and set a $1.80 price target (down previously from $3.50) on shares of Akoya Biosciences in a research note on Tuesday, March 25th. Seven research analysts have rated the stock with a hold rating, According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $3.21.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.